Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far. A new multi-chamber organoid that mirrors the heart’s intricate structure enables scientists to advance screening platforms for drug development, toxicology studies, and understanding heart development. The...Continue Reading

Vienna, Austria – 02 November 2023 – HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, today announced the closing of a € 4.5 million Pre-Series A round co-led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures....Continue Reading

VIENNA, Austria – 5 October 2022 – HeartBeat.bio AG has entered a collaboration with Boehringer Ingelheim for the investigation of human cardiac organoids (Cardioids) for high-throughput early safety assessment and drug discovery.Continue Reading

VIENNA and SAN JOSE, CA – Sept. 12 – HeartBeat.bio AG, a biotech company developing cardiac organoids (Cardioids) for drug discovery, and Molecular Devices, LLC., a leading provider of high-performance life science solutions, have entered into a co-development agreement...Continue Reading

Vienna, Austria – 20 May 2021 – HeartBeat.bio AG, a biotech company focusing on cardiac drug discovery based on heart organoids....Continue Reading

Vienna, Austria – 04 May 2021 – HeartBeat.bio AG, a spin-off company of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA)...Continue Reading